Treatment of thrice-negative breast cancer in a patient with metabolic syndrome
https://doi.org/10.17709/2409-2231-2021-8-1-6
Abstract
Breast cancer (BC) remains one of the most common diseases of the female population. According to statistics, breast cancer is detected in every eighth woman. Approximately 20‑24% of breast cancer patients are diagnosed with triple negative breast cancer. Triple‑negative breast cancer is characterized by an aggressive clinical course, a higher relapse rate, and low overall survival. According to statistics, the median survival rate for women with metastatic triple‑negative breast cancer is less than one year. We demonstrate a successful case of treatment of a 60‑year‑old woman diagnosed with triple negative breast cancer on the right, edematous‑infiltrative form, St IIIC cT4bN3M0 on the background of metabolic syndrome. Antitumor treatment lasted 1 year and consisted of three stages: systemic chemotherapy, surgical treatment (radical mastectomy), and adjuvant radiation therapy. After the treatment, remission was achieved. The patient is alive and has a relapse‑free period of 3 years.
Conclusion. Despite the severe concomitant pathology in the observed patient, we received a positive result of multi‑ stage therapy, where cytotoxic chemotherapy was the basic treatment for a woman with triple negative breast cancer.
About the Authors
G. E. Roitberg
N.I.Pirogov Russian National Research Medical University (RNRMU); “Medicinа”
Russian Federation
Russian Federation
Grigory E. Roitberg – academician of Russian Academy of Science, Dr. Sci. (Med.), professor, head of the department of therapy, general medical practice and nuclear medicine; President
SPIN: 1032-9122, AuthorID: 218525
1 Ostrovityanova str., Moscow 117997
J. V. Dorosh
N.I.Pirogov Russian National Research Medical University (RNRMU)
Russian Federation
Russian Federation
Janna V. Dorosh – Cand. Sci. (Med.), associate lecturer, department of therapy, general medical practice and nuclear medicine
SPIN: 3592-4274, AuthorID: 663889
1 Ostrovityanova str., Moscow 117997
O. Yu. Anikeeva
“Medicinа”
Russian Federation
Russian Federation
Olga Yu. Anikeeva – Dr. Sci. (Med.), chief of the oncological center
SPIN: 7581-8769, AuthorID: 696308
10 2nd Tverskaya-Yamskaya lane, Moscow125047
References
1. Lebert JM, Lester R, Powell E, Seal M, McCarthy J. Advances in the systemic treatment of triple-negative breast cancer. Curr Oncol. 2018 Jun;25(Suppl 1):S142–S150. https://doi.org/10.3747/co.25.3954
2. Roytberg GE, Kondratova NV. Screening and prophylaxis of breast cancer in primary care. Vestnik Roszdravnadzora. 2018;1:57–61. (In Russian).
3. Astashov VV, Volkova MS, Kazakov OV, Ivanova EB, Larionov PM, CHepik VI, et al. Regional lymphatic bed in experimental induction of breast cancer in the conditions of preventive phytotherapy. A life without danger. Health. Prevention. Longevity. 2012;7(2):109–115. (In Russian).
4. Vladimirova LYu, Storozhakova AE, Snezhko TA, Strakhova LK, Abramova NA, Kabanov SN, et al. Hormone-positive HER2-negative metastatic breast cancer: decision making in real clinical practice. South Russian Journal of Cancer. 2020;1(2):46–51. (In Russian). https://doi.org/10.37748/2687-0533-2020-1-2-6
5. Jhan J-R, Andrechek ER. Triple-negative breast cancer and the potential for targeted therapy. Pharmacogenomics. 2017 Nov;18(17):1595–1609. https://doi.org/10.2217/pgs-2017-0117
6. Hodorovich OS, Snigireva GP, CHkhikvadze VD, Oksanchuk EA, Meskih EV, Novikova EI. BRCA-associated breast cancer. A case from practice. Difficult Patient. 2016;14(10-11):46–49. (In Russian).
7. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017 Jan;67(1):7–30. https://doi.org/10.3322/caac.21387
8. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429–4434. https://doi.org/10.1158/1078-0432.CCR-06-3045
9. Abramson VG, Lehmann BD, Ballinger TJ, Pietenpol JA. Subtyping of triple-negative breast cancer: implications for therapy. Cancer. 2015 Jan 1;121(1):8–16. https://doi.org/10.1002/cncr.28914
10. Kit OI, Popova NN, Shikhlyarova AI, Frantsiyants EM, Moiseenko TI, Menshenina AP, et al. Development of postcastration syndrome and corrective effect of xenon in exponential dose regimen in young patients with gynecological cancers. South Russian Journal of Cancer. 2020;1(3):6–17. (In Russian). https://doi.org/10.37748/2687-0533-2020-1-3-1
11. Savci-Heijink CD, Halfwerk H, Hooijer GKJ, Horlings HM, Wesseling J, van de Vijver MJ. Retrospective analysis of metastatic behaviour of breast cancer subtypes. Breast Cancer Res Treat. 2015 Apr;150(3):547–557. https://doi.org/10.1007/s10549-015-3352-0
12. Secundova MA, Sdvizhkov AM, Yakovenko IYu. Three times negative breast cancer – treatment features. Palliative medicine and rehabilitation. 2017;(4):13–18. (In Russian).
13. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010 Nov 11;363(20):1938–1948. https://doi.org/10.1056/NEJMra1001389
14. Friedenreich CM. Physical activity and breast cancer: review of the epidemiologic evidence and biologic mechanisms. Recent Results Cancer Res. 2011;188:125–139. https://doi.org/10.1007/978-3-642-10858-7_11
15. Whiteman MK, Hillis SD, Curtis KM, McDonald JA, Wingo PA, Marchbanks PA. Body mass and mortality after breast cancer diagnosis. Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):2009–2014. https://doi.org/10.1158/1055-9965.EPI-05-0106
16. Daling JR, Malone KE, Doody DR, Johnson LG, Gralow JR, Porter PL. Relation of body mass index to tumor markers and survival among young women with invasive ductal breast carcinoma. Cancer. 2001 Aug 15;92(4):720–729. https://doi.org/10.1002/1097-0142(20010815)92:4<720::aid-cncr1375>3.0.co;2-t
17. Wolf I, Sadetzki S, Gluck I, Oberman B, Ben-David M, Papa MZ, et al. Association between diabetes mellitus and adverse characteristics of breast cancer at presentation. Eur J Cancer. 2006 May;42(8):1077–1082. https://doi.org/10.1016/j.ejca.2006.01.027
18. Roytberg GE, Ushakova TI, Sharhun OO, Dorosh JV. The Integrated Approach to Diagnostics of Metabolic Syndrome in Clinical Practice. Cardiology. 2012;52(10):45–50. (In Russian).
19. Phipps AI, Malone KE, Porter PL, Daling JR, Li CI. Body size and risk of luminal, HER2-overexpressing, and triple-negative breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):2078–2086. https://doi.org/10.1158/1055-9965.EPI-08-0206
20. Titov KS, Kazakov AM, Baryshnikova MA, Ryabchikov DA, Chulkova SV, Zaryanov DA. Some Molecular and Immunologic Prognostic Factors of Triple Negative Breast Cancer. Gynecological oncology. 2019;4(32):26–34. (In Russian).
21. Rose DP, Gracheck PJ, Vona-Davis L. The Interactions of Obesity, Inflammation and Insulin Resistance in Breast Cancer. Cancers (Basel). 2015 Oct 26;7(4):2147–2168. https://doi.org/10.3390/cancers7040883
22. Barbarroja N, Lopez-Pedrera C, Garrido-Sanchez L, Mayas MD, Oliva-Olivera W, Bernal-Lopez MR, et al. Progression from high insulin resistance to type 2 diabetes does not entail additional visceral adipose tissue inflammation. PLoS One. 2012;7(10):e48155. https://doi.org/10.1371/journal.pone.0048155
Review
For citations:
Roitberg G.E., Dorosh J.V., Anikeeva O.Yu. Treatment of thrice-negative breast cancer in a patient with metabolic syndrome. Research and Practical Medicine Journal. 2021;8(1):62-68. (In Russ.) https://doi.org/10.17709/2409-2231-2021-8-1-6
Views:
40251
Email this article 